The microRNA expression in lymph node metastasis of gastric cancer
| Project/Area Number |
24791439
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | National Cancer Center Japan (2013-2014)
Fukushima Medical University (2012) |
|---|
Principal Investigator |
SAITO Motonobu 独立行政法人国立がん研究センター, 研究所, 研究員 (90611749)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 胃癌 / CDX2 / マイクロRNA / 炎症発癌 / 胃癌リンパ節転移 / リンパ節転移 |
|---|
| Outline of Final Research Achievements |
We confirmed that decreased expression of CDX2 by immunohistochemistry was associated with poor cancer-specific survival in our 210 gastric cancer cases, consistent with several previous studies. We further investigated the mechanisms of CDX2 suppression, including the IL-6/STAT3 and p53 pathways. We confirmed that CDX2 was suppressed by activation of the IL-6/STAT3 pathway via miR-181b in vitro. We further revealed that gastric cancers, particularly those that are undifferentiated, with CDX2-negative expression are associated with p53-negative staining. The activation of the IL-6/STAT3 pathway suppressed miR-34a, which is induced by p53, suggesting that the activation of this inflammation signaling pathway suppresses the p53 pathway in tumors without TP53 mutation, resulting in poor prognostic outcome. In conclusion, the activation of the IL-6/STAT3 pathway contributes to gastric carcinogenesis through suppression of CDX2 and inactivation of p53, resulting in poor prognostic outcome.
|
Report
(4 results)
Research Products
(4 results)
-
[Journal Article] A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma.2014
Author(s)
Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H, Watanabe SI, Tsuta K, Kumamoto K, Takenoshita S, Yokota J, Harris CC, Kohno T.
-
Journal Title
Clinical Cancer Research
Volume: 20（18）
Issue: 18
Pages: 4784-93
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma2013
Author(s)
Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, Kazandjian D, Welsh JA, Oue N, Saito M, Miyashita M, Uchida E, Takizawa T, Takenoshita S, Skaug V, Mollerup S, Haugen A, Yokota J, Harris CC.
-
Journal Title
Cancer Research
Volume: 73（13）
Pages: 3821-31
Related Report
Peer Reviewed
-
-
